{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:31:17Z","timestamp":1789140677752,"version":"build-2803163510"},"reference-count":33,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Drug-induced agranulocytosis is a rare but life-threatening adverse reaction associated with numerous non-chemotherapy drugs. Management relies on immediate drug withdrawal, infection control, and, in selected patients, administration of granulocyte-colony stimulating factor (G-CSF). This review summarizes current knowledge on the determinants of epidemiology, clinical presentation, hematologic and biologic features, comorbidities, and outcomes influencing the decision to introduce G-CSF in drug-induced agranulocytosis. Evidence from observational studies and meta-analyses suggests that G-CSF shortens neutropenia duration and hospitalization, although its impact on mortality remains uncertain. The decision to use G-CSF should consider initial neutrophil count, presence of severe infection or sepsis, age, and comorbidities. Despite the accumulated experience, randomized controlled trials are still lacking, and treatment algorithms remain empirical.<\/jats:p>","DOI":"10.3390\/hematolrep18010014","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T10:03:29Z","timestamp":1770113009000},"page":"14","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Factors Influencing the Use of G-CSF in Drug-Induced Agranulocytosis"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7914-7616","authenticated-orcid":false,"given":"Emmanuel","family":"Andr\u00e8s","sequence":"first","affiliation":[{"name":"Service de M\u00e9decine Interne, H\u00f4pital de Hautepierre, H\u00f4pitaux Universitaires de Strasbourg, 67000 Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Edouard","family":"Terrade","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Interne, H\u00f4pital de Hautepierre, H\u00f4pitaux Universitaires de Strasbourg, 67000 Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7166-9057","authenticated-orcid":false,"given":"Xavier","family":"Jannot","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Interne, H\u00f4pital de Hautepierre, H\u00f4pitaux Universitaires de Strasbourg, 67000 Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel","family":"Lorenzo-Villalba","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Interne, H\u00f4pital de Hautepierre, H\u00f4pitaux Universitaires de Strasbourg, 67000 Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00228-013-1618-1","article-title":"Drug-induced agranulocytosis in the Berlin case-control surveillance study","volume":"70","author":"Huber","year":"2014","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"319","DOI":"10.7326\/0003-4819-148-4-200802190-00015","article-title":"Agranulocytosis induced by nonchemotherapy drugs","volume":"148","author":"Vidal","year":"2008","journal-title":"Ann. Intern. Med."},{"key":"ref_3","first-page":"60","article-title":"Development and validation of a cell-based methodology to evaluate filgrastim relative affinity to granulocyte colony-stimulating factor receptor","volume":"19","year":"2025","journal-title":"J. Immunoass. Immunochem."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1592\/phco.19.4.299.30941","article-title":"Nonchemotherapy drug-induced agranulocytosis: A review of 118 patients treated with colony-stimulating factors","volume":"19","author":"Beauchesne","year":"1999","journal-title":"Pharmacotherapy"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/pds.1542","article-title":"Agranulocytosis and Aplastic Anaemia Study Group of Barcelona. Use of granulocyte colony-stimulating factor (G-CSF) and outcome in patients with non-chemotherapy agranulocytosis","volume":"17","author":"Puig","year":"2008","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","article-title":"2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours","volume":"47","author":"Aapro","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Rattay, B., and Benndorf, R.A. (2021). Drug-Induced Idiosyncratic Agranulocytosis\u2014Infrequent but Dangerous. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.727717"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"657","DOI":"10.7326\/0003-4819-146-9-200705010-00009","article-title":"Systematic review: Agranulocytosis induced by nonchemotherapy drugs","volume":"146","author":"Andersohn","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0953-6205(02)00085-7","article-title":"Modern management of non-chemotherapy drug-induced agranulocytosis: A monocentric cohort study of 90 cases and review of the literature","volume":"13","author":"Maloisel","year":"2002","journal-title":"Eur. J. Intern. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1182\/blood.V86.3.1177.1177","article-title":"HLA associations in clozapine-induced agranulocytosis","volume":"86","author":"Yunis","year":"1995","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1182\/asheducation-2017.1.187","article-title":"Non-chemotherapy drug-induced neutropenia: Key points to manage the challenges","volume":"2017","author":"Curtis","year":"2017","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1001\/archinte.165.8.869","article-title":"Population-based drug-induced agranulocytosis","volume":"165","author":"Vidal","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.pharma.2020.02.004","article-title":"Agranulocytoses m\u00e9dicamenteuses idiosyncrasiques: Analyse de 7 ans dans un h\u00f4pital universitaire fran\u00e7ais [Idiosyncratic drug-induced agranulocytosis: 7 year-analysis in a French university hospital]","volume":"78","author":"Duwez","year":"2020","journal-title":"Ann. Pharm. Fr."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5641","DOI":"10.1182\/bloodadvances.2023012316","article-title":"Rates of severe neutropenia and infection risk in patients treated with deferiprone: 28 years of data","volume":"8","author":"Badawy","year":"2024","journal-title":"Blood Adv."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Cismaru, A.L., Rudin, D., Iba\u00f1ez, L., Liakoni, E., Bonadies, N., Kreutz, R., Carvajal, A., Lucena, M.I., Martin, J., and Sancho Ponce, E. (2020). Genome-Wide Association Study of Metamizole-Induced Agranulocytosis in European Populations. Genes, 11.","DOI":"10.3390\/genes11111275"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s12020-025-04372-y","article-title":"Antithyroid drugs and the dose-risk balance: A meta-analysis on agranulocytosis in hyperthyroidism","volume":"90","author":"Brun","year":"2025","journal-title":"Endocrine"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1517\/17425255.2015.985649","article-title":"Current understanding of the mechanisms of idiosyncratic drug-induced agranulocytosis","volume":"11","author":"Johnston","year":"2015","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.revmed.2010.04.005","article-title":"Neutrop\u00e9nies auto-immunes [Autoimmune neutropenia]","volume":"32","author":"Martin","year":"2011","journal-title":"Rev. Med. Interne"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Lorenzo-Villalba, N., Alonso-Ortiz, M.B., Maouche, Y., Zulfiqar, A.A., and Andr\u00e8s, E. (2020). Idiosyncratic Drug-Induced Neutropenia and Agranulocytosis in Elderly Patients. J. Clin. Med., 9.","DOI":"10.3390\/jcm9061808"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Wu, S., Huang, L., Chen, J., Xie, X., Huang, S., and Huang, X. (2025). Non-chemotherapy drugs inducing agranulocytosis: A disproportionality analysis based on the FAERS database. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1525307"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/j.ejim.2017.08.018","article-title":"History and outcome of febrile neutropenia related to non-chemotherapy drugs: A retrospective study of the Strasbourg\u2019s agranulocytosis cohort","volume":"46","author":"Maloisel","year":"2017","journal-title":"Eur. J. Intern. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1517\/14740338.6.3.323","article-title":"Non-chemotherapy drug-induced agranulocytosis","volume":"6","author":"Garbe","year":"2007","journal-title":"Expert. Opin. Drug Saf."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","article-title":"Management of febrile neutropaenia: ESMO Clinical Practice Guidelines \u2020","volume":"27","author":"Klastersky","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1200\/JCO.2017.77.6211","article-title":"Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/j.lpm.2014.02.007","article-title":"Autoimmune neutropenia","volume":"43","author":"Lamy","year":"2014","journal-title":"Presse Med."},{"key":"ref_27","first-page":"525","article-title":"Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: A systematic review","volume":"23","author":"Pfeil","year":"2015","journal-title":"Support. Care Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Wang, Y., Li, X., Yang, Q., Wang, W., Zhang, Y., Liu, J., Zheng, L., and Zha, B. (2019). Granulocyte-Colony-Stimulating Factor Effectively Shortens Recovery Duration in Anti-Thyroid-Drug-Induced Agranulocytosis: A Systematic Review and Meta-Analysis. Front. Endocrinol., 10.","DOI":"10.3389\/fendo.2019.00789"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Garc\u00eda G\u00f3mez, C., Navarro, E., Alc\u00e1zar, V., L\u00f3pez-Guzm\u00e1n, A., Arrieta, F., Anda, E., Biagetti, B., Guerrero-P\u00e9rez, F., Villabona, C., and de Ass\u00edn Valverde, A.R. (2023). Therapeutic Management and Long-Term Outcome of Hyperthyroidism in Patients with Antithyroid-Induced Agranulocytosis: A Retrospective, Multicenter Study. J. Clin. Med., 12.","DOI":"10.3390\/jcm12206556"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/JCP.0000000000000715","article-title":"Clozapine-Associated Agranulocytosis Treatment With Granulocyte Colony-Stimulating Factor\/Granulocyte-Macrophage Colony-Stimulating Factor: A Systematic Review","volume":"37","author":"Lally","year":"2017","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40348-023-00160-8","article-title":"Metamizole-induced agranulocytosis (MIA): A mini review","volume":"10","author":"Goppelt","year":"2023","journal-title":"Mol. Cell Pediatr."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1089\/thy.1999.9.29","article-title":"Granulocyte Colony-Stimulating Factor (G-CSF) Does Not Improve Recovery from Antithyroid Drug-Induced Agranulocytosis: A Prospective Study","volume":"9","author":"Fukata","year":"1999","journal-title":"Thyroid"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1093\/jnci\/djk028","article-title":"Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy","volume":"99","author":"Hershman","year":"2007","journal-title":"J. Natl. Cancer Inst."}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/18\/1\/14\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T10:44:38Z","timestamp":1770115478000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/18\/1\/14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["hematolrep18010014"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep18010014","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]}}}